Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

计划入组 260 人 · 首次发布于 2025 年 9 月 3 日

Capecitabine in Low Risk Triple Negative Breast Cancer

计划入组 198 人 · 首次发布于 2025 年 1 月 22 日

Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer

计划入组 100 人 · 首次发布于 2019 年 4 月 9 日

Triple-Negative Breast Cancer (formulated vaccine)

CLX-001

PKC theta inhibitor (cancer/triple negative breast cancer)

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

JAPAN BREAST CANCER RESEARCH GROUP

Japan

International Breast Cancer Research Foundation

United States

Soluble HER2 Drives CD8⁺ T-Cell Exhaustion and Limits Immunotherapy Response in HER2-Low Triple-Negative Breast Cancer

Immutep Completes Enrollment in Phase II AIPAC-003 Trial for Metastatic Breast Cancer

Immutep's Efti Shows Promise in Lung and Head & Neck Cancers, Advances Autoimmune Program